Inhaled Dual PDE3/4 Inhibitor Ensifentrine for Chronic Obstructive Pulmonary Disease: A Potential Therapeutic Perspective

Am J Respir Crit Care Med. 2024 Jan 15;209(2):223-224. doi: 10.1164/rccm.202307-1143LE.

Authors

Qiming Gan¹, Yanjuan Wu¹, Xiaofen Su¹, Jingcun Wang¹, Haojie Zhang¹, Nuofu Zhang¹, Kang Wu¹

Affiliation

¹ State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, National Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Administration, Inhalation
Adrenal Cortex Hormones / therapeutic use
Asthma* / drug therapy
Bronchodilator Agents / therapeutic use
Humans
Isoquinolines / pharmacology
Isoquinolines / therapeutic use
Phosphodiesterase 3 Inhibitors / pharmacology
Phosphodiesterase 3 Inhibitors / therapeutic use
Pulmonary Disease, Chronic Obstructive* / drug therapy
Pyrimidinones*

Substances

Phosphodiesterase 3 Inhibitors
ensifentrine
Isoquinolines
Bronchodilator Agents
Adrenal Cortex Hormones
Pyrimidinones

Grants and funding

8210010336/Young Scientist Fund of National Natural Science Foundation of China